|
Market Closed -
Nasdaq
08:00:00 27/02/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 72.82 USD | +0.03% |
|
-.--% | +0.96% |
| 29/09 | Pharma sector doubles down on AI to slash costs, timelines | RE |
| 21/09 | Pharma sector doubles down on AI to slash costs, timelines | RE |
| Market Cap | 11.3B 10.03B 9.38B 8.55B 16.1B 1,088B 16.32B 114B 43.95B 554B 42.42B 41.5B 1,779B | P/E 2024 |
-10.1x | P/E 2025 | -14.5x |
|---|---|---|---|---|---|
| Enterprise Value | 9.65B 8.57B 8.02B 7.3B 13.75B 929B 13.94B 96.97B 37.54B 473B 36.23B 35.45B 1,520B | EV / Sales 2024 |
181x | EV / Sales 2025 | 492x |
| Free-Float |
10.55% | Yield 2024 * |
-
| Yield 2025 | - |
Last Transcript: Avidity Biosciences, Inc.
| 1 day | +0.03% | ||
| Current year | +0.96% |
| Current year | 72 |  | 73.06 |
| 1 year | 44.28 | | 73.06 |
| 3 years | 4.82 | | 73.06 |
| 5 years | 4.82 | | 73.06 |
| 10 years | 4.82 | | 73.06 |
| Manager | Title | Age | Since |
|---|---|---|---|
John McKenna
PSD | President | - | 27/02/2026 |
Eduard Marti
TRE | Treasurer | - | 27/02/2026 |
Jaime S. Huertas
SEC | Corporate Secretary | - | 27/02/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Jaime S. Huertas
BRD | Director/Board Member | - | 27/02/2026 |
Eduard Marti
BRD | Director/Board Member | - | 27/02/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 27/2/26 | Issuer sale | Director | 110,073 | 0.0766% | ||
| 27/2/26 | Issuer sale | Chief Technology Officer | 547,865 | 0.3814% | ||
| 27/2/26 | Issuer sale | General Counsel | 302,054 | 0.2103% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.03% | -.--% | +69.35% | +1,041.38% | 11.3B | |
| -0.62% | -2.71% | +39.30% | +114.07% | 1,025B | |
| -2.30% | -4.44% | +39.03% | +66.07% | 623B | |
| -0.63% | -1.96% | +6.36% | +74.38% | 459B | |
| -1.03% | -2.82% | +59.56% | +39.69% | 355B | |
| -0.03% | -3.96% | +23.63% | +39.35% | 336B | |
| -1.58% | -0.76% | +13.50% | +25.77% | 270B | |
| -2.02% | -2.97% | -3.25% | +8.38% | 247B | |
| -3.38% | +0.30% | +36.44% | +51.54% | 220B | |
| -1.04% | -1.46% | +32.70% | +96.82% | 183B | |
| Average | -1.26% | -1.70% | +31.66% | +155.75% | 372.95B | |
| Weighted average by Cap. | -1.24% | -2.10% | +30.63% | +72.24% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 10.9M 9.68M 9.05M 8.25M 15.53M 1.05B 15.74M 109M 42.39M 534M 40.91M 40.03M 1.72B | 18.76M 16.66M 15.58M 14.2M 26.73M 1.81B 27.09M 188M 72.96M 920M 70.42M 68.89M 2.95B |
| Net income | -322M -286M -268M -244M -459M -31.03B -466M -3.24B -1.25B -15.8B -1.21B -1.18B -50.76B | -685M -608M -569M -518M -976M -65.92B -989M -6.88B -2.66B -33.57B -2.57B -2.51B -108B |
| Net Debt | -1.49B -1.33B -1.24B -1.13B -2.13B -144B -2.16B -15.02B -5.81B -73.29B -5.61B -5.49B -235B | -1.65B -1.46B -1.37B -1.25B -2.35B -159B -2.38B -16.56B -6.41B -80.79B -6.19B -6.05B -259B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- RNA Stock
Select your edition
All financial news and data tailored to specific country editions
